U.S. patent application number 16/569909 was filed with the patent office on 2020-01-02 for stable multiparticulate pharmaceutical composition of rosuvastatin.
This patent application is currently assigned to Sun Pharma Advanced Research Company Ltd.. The applicant listed for this patent is Sun Pharma Advanced Research Company Ltd.. Invention is credited to Nitin Bhalachandra Dharmadikari, Ashwini Gadkari, Yashoraj Zala.
Application Number | 20200000803 16/569909 |
Document ID | / |
Family ID | 58097244 |
Filed Date | 2020-01-02 |
United States Patent
Application |
20200000803 |
Kind Code |
A1 |
Dharmadikari; Nitin Bhalachandra ;
et al. |
January 2, 2020 |
STABLE MULTIPARTICULATE PHARMACEUTICAL COMPOSITION OF
ROSUVASTATIN
Abstract
A stable multi-particulate pharmaceutical composition comprising
pellets, the pellets comprising a mixture of rosuvastatin or its
pharmaceutically acceptable salts as a sole active ingredient, one
or more osmotic release modifiers and one or more stabilizers.
Inventors: |
Dharmadikari; Nitin
Bhalachandra; (Mumbai, IN) ; Zala; Yashoraj;
(Mumbai, IN) ; Gadkari; Ashwini; (Mumbai,
IN) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Sun Pharma Advanced Research Company Ltd. |
Mumbai |
|
IN |
|
|
Assignee: |
Sun Pharma Advanced Research
Company Ltd.
Mumbai
IN
|
Family ID: |
58097244 |
Appl. No.: |
16/569909 |
Filed: |
September 13, 2019 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15042479 |
Feb 12, 2016 |
10413543 |
|
|
16569909 |
|
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 9/1623 20130101;
A61K 9/1617 20130101; A61K 9/5047 20130101; A61K 9/1635 20130101;
A61K 9/1611 20130101; A61K 9/4858 20130101; A61K 9/5042 20130101;
A61K 31/505 20130101; A61K 9/5031 20130101; A61K 9/1652 20130101;
A61K 9/4866 20130101 |
International
Class: |
A61K 31/505 20060101
A61K031/505; A61K 9/16 20060101 A61K009/16; A61K 9/48 20060101
A61K009/48; A61K 9/50 20060101 A61K009/50 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 1, 2015 |
IN |
3351/MUM/2015 |
Claims
1. The stable multi-particulate pharmaceutical composition of,
wherein an average particle size of the pellets is from about 0.4
mm to 0.8 mm, the rosuvastatin is rosuvastatin calcium, the
stabilizer is an alkaline earth metal salt and the osmotic release
modifier is an inorganic salt of monovalent cation.
2. The stable multi-particulate pharmaceutical composition of claim
1, wherein the alkaline earth metal salt is magnesium oxide and the
inorganic salt of a monovalent cation is sodium citrate.
3. The stable multi-particulate pharmaceutical composition of claim
1 prepared by a process comprising: mixing the rosuvastatin or its
pharmaceutically acceptable salt, one or more osmotic release
modifiers and one or more stabilizers to form granules; extruding
the granules; spheronizing the granules; and sizing the granules to
have an particle size of from 0.4 mm to 0.8 mm.
4. A method of treating hyperlipidemia comprising orally
administering to a human in need thereof the stable
multi-particulate pharmaceutical composition of claim 1, wherein
the oral administration comprises administration of 5 mg to 40 mg
of rosuvastatin per day.
5. The method of claim 4, wherein the oral administration comprises
sprinkling the multi-particulate pharmaceutical composition on
food.
6. A stable multi-particulate pharmaceutical composition comprising
pellets filled in a capsule sachet or pouch or compressed into a
dispersible tablet, the pellets comprising at least 5% by weight of
a pharmaceutically acceptable salt of rosuvastatin as a sole active
ingredient, by weight of the pellets.
7. The stable multi-particulate pharmaceutical composition of claim
6, comprising 5 to 15% by weight of the pharmaceutically acceptable
salt of rosuvastatin as a sole active ingredient, by weight of the
pellets.
8. The stable multi-particulate pharmaceutical composition of claim
6, wherein an average particle size of the pellets is from about
0.4 mm to 0.8 mm, the pharmaceutically acceptable salt of
rosuvastatin is rosuvastatin calcium, further comprising a
stabilizer consisting of an alkaline earth metal salt and an
osmotic release modifier consisting of an inorganic salt of a
monovalent cation.
9. The stable multi-particulate pharmaceutical composition of claim
8, wherein the alkaline earth metal salt is magnesium oxide and the
inorganic salt of a monovalent cation is sodium citrate.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a Continuation Application of U.S.
application Ser. No. 15/042,479, filed on Feb. 12, 2016, which
claims priority from Indian Patent Application No. 3351/MUM/2015,
filed on Sep. 1, 2015, the contents of all of which are
incorporated herein by reference in their entirety.
FIELD OF INVENTION
[0002] The present invention relates to a stable, multi-particulate
pharmaceutical composition of rosuvastatin or its pharmaceutically
acceptable salt.
BACKGROUND
[0003] Rosuvastatin is marketed as rosuvastatin calcium in the form
of tablets containing 5, 10, 20 and 40 mg of rosuvastatin calcium,
under the brand name of Crestor. It is indicated in patients with
primary hyperlipidemia as an adjunct to diet to reduce elevated
total cholesterol, low density lipoprotein and triglyceride levels
and to increase high density lipoprotein. As The prevalence of
hyperlipidemia increases with age and requires chronic therapy,
these HMG-CoA inhibitors, such as rosuvastatin calcium, are
generally prescribed to patients for the rest of their lives.
Further, it is known that geriatric populations generally may need
to take more than one medication.
[0004] Solid unit oral dosage forms are available in a variety of
sizes and shapes. It is always preferable to design a dosage form
that is patient compliant in terms of adhering to the therapy.
Sometimes such solid dosage forms pose problems while swallowing as
a result of, example, their size, stickiness, taste, aftertaste or
frequency of administration. Particularly, in patients suffering
from dysphagia, the swallowing of solid oral dosage form may be
very painful, if not impossible. Thus, there is a need for a dosage
form that eases oral administration.
SUMMARY OF THE INVENTION
[0005] The present inventors have discovered a novel
multi-particulate pharmaceutical composition, each particle having
a higher percentage of rosuvastain or its pharmaceutically
acceptable salt, loaded into it. The high percentage loading makes
the single unit dosage form of the pharmaceutical composition
compact, and causes it to contain fewer excipients, allowing the
patient to administer it by sprinkling onto a minimum portion, for
instance, a teaspoon, of a vehicle. The multiparticulate
composition has been found to be not only patient compliant but
also chemically stable throughout the shelf life of the
product.
[0006] The present invention provides a stable multi-particulate
pharmaceutical composition comprising pellets, the pellets
comprising a mixture of rosuvastatin or its pharmaceutically
acceptable salts as a sole active ingredient, one or more osmotic
release modifiers and one or more stabilizers. Also, the present
inventors have discovered a novel stable multi-particulate
pharmaceutical composition comprising pellets, the pellets
comprising at least 5% by weight of pharmaceutically acceptable
salt of rosuvastatin as a sole active ingredient, by weight of the
pellets.
[0007] The present inventors have discovered that the osmotic
release modifiers are critical to accelerate release of
rosuvastatin from the pellets. Such a stable multi-particulate
pharmaceutical composition of rosuvastatin calcium is particularly
advantageous as it can be administered by sprinkling on soft food,
such as applesauce, pudding, custard, oatmeal or yoghurt. The
pellets are of such a size that they escape chewing or mastication
and are palatable. Thus a stable, multi-particulate pharmaceutical
composition of rosuvastatin calcium that is very patient compliant
is presented. Alternatively, the pellets can also be administered
via a nasogastric tubing for hospitalized patients.
DETAILED DESCRIPTION OF THE INVENTION
[0008] The term `pellet` as used herein means any particle that is
prepared by process of agglomeration of, for example, powder. The
agglomeration may be achieved by either granulation, compaction,
extrusion, slugging, drug loading or the like. Such a pellet
preferably has good flow, and preferably has an aspect ratio of
about 1 to about 2. Further, the pellets may be spherical or oval
with a smooth surface and may have a density higher than the
powder.
[0009] The term "mixture" as used herein means that the
rosuvastatin or the pharmaceutically acceptable salts thereof are
mixed uniformly with excipients of various categories such as
stabilizers, alkalizing agents, buffering agents, disintegrant or
diluents etc.
[0010] The term `stable` as used herein means that when the
multi-particulate pharmaceutical composition of the present
invention is stored at accelerated conditions of 40.degree. C./75%
relative humidity, the rosuvastatin lactone impurity is less than
0.5% by weight of the composition. In preferred embodiments, the
lactone impurity is less than 0.1% by weight of the composition.
Further the multi-particulate pharmaceutical composition is said to
be stable when the total impurities, which include anti-isomer
(impurity A), 5-keto rosuvastatin, rosuvastatin lactone (impurity
B), dehydro rosuvastatin acid, 5-keto rosuvastatin, dehydro
lactone, dehydro triene and the highest unknown impurity, are less
than 1.5%, preferably less than 1% by weight.
[0011] The term `sprinkle` as used herein means that the
multi-particulate pharmaceutical composition is to be added onto
food or any edible material, or liquid, such as water, juices etc.
before administration. The pellets of the multi-particulate
pharmaceutical composition may be packed in sachet or pouch or
filled into capsules and may be sprinkled onto food or edible
material or into a liquid. Alternatively, multi-particulate
pharmaceutical composition may also be in the form of a dispersible
tablet which can be dispersed in a liquid to yield a dispersion of
the individual particles before drinking. The multi-particulate
pharmaceutical composition of the present invention is configured
so as to be administered by initially opening a sachet or pouch or
capsule filled with it or transferring it onto a vehicle, such as a
soft food, for example applesauce, pudding, custard, oatmeal and
yoghurt. Then, the vehicle into which the composition is sprinkled
is swallowed immediately. It will be appreciated that the
multi-particulate pharmaceutical composition of the present
disclosure is not designed so as to be swallowed as a whole, and is
meant to be sprinkled onto the vehicle. Alternatively, geriatric
patients who have difficulty swallowing may adding the composition
of the present invention that has been filled into sachet or pouch
or capsule, into a liquid medium, such as water, to obtain a
suspension. The suspension may be then orally administered through,
e.g., a nasogastric tube into the stomach.
[0012] Rosuvastatin used in the multi-particulate pharmaceutical
composition of the present disclosure, may be in different salt
forms, such as alkali metal salts, such as lithium, sodium,
potassium, and cesium and the like; and alkaline earth metal salts,
such as beryllium, magnesium, and calcium salts and the like. The
percentages of the rosuvastatin are expressed in terms of its acid
and not salt. In one specific embodiment, calcium salt of
rosuvastatin is used. It may be used as a crystalline or amorphous
form. The particle size distribution of the rosuvastatin calcium
may be such that D.sub.10 ranges from about 2 microns to 20
microns, D.sub.50 ranges from 30 microns to 70 about microns and
D.sub.90 ranges from about 120 microns to 200 microns, preferably,
the D.sub.10 is about 5 to 10 microns, D.sub.50 is about 40 to 60
microns and D.sub.90 is about 160 to 180 microns. In one most
preferred embodiment, the particle size distribution of the
rosuvastatin calcium is such that D.sub.10 is about 6 microns,
D.sub.50 is about 50 microns and D.sub.90 is about 160 microns.
Generally, D.sub.10 is not more than 20 microns, D.sub.50 is about
25 microns to 50 microns and D.sub.90 is not more than 200 microns.
In one embodiment, the stable multi-particulate pharmaceutical
composition of the present disclosure comprises, in one embodiment,
at least 5% by weight of pharmaceutically acceptable salt of
rosuvastatin as a sole active ingredient, by weight of the pellets.
In one specific embodiment, the rosuvastatin is present in the form
of its calcium salt. In a preferred embodiment, the amount of
rosuvastatin or its salt ranges from about 5% by weight to about
30% by weight, preferably 5% by weight to 15% by weight of the
pellets of the multi-particulate pharmaceutical composition. All
the percentages of the rosuvastatin are expressed in terms of its
free acid and not salt.
[0013] In one embodiment, for a strength of 5 mg of rosuvastatin,
the total weight of the pellets is about 50 mg, for 10 mg of
rosuvastatin, the total weight of the pellets is about 100 mg; for
20 mg of rosuvastatin; the total weight of the pellets is about 200
mg; for 40 mg of rosuvastatin, the total weight of the pellets is
about 400 mg. It will be appreciated by person skilled in the art
that the pellet volume is very compact and the patients can
administer the prescribed dose of rosuvastatin with the help of
very small portions of a vehicle, such as soft food, apple sauce
and the like.
[0014] The multiparticulate composition of the present invention
may contain osmotic release modifiers that accelerate the release
of rosuvastatin from the pellets. Such osmotic release modifiers
include agents that have good affinity for water, and which
dissolve quickly when in contact with an aqueous medium. For the
purpose of this disclosure, the osmotic release modifiers do not
include large molecular weight carbohydrates such as, for instance,
microcrystalline celluloses or sugars of sugar spheres. The osmotic
release modifiers are rather ones that may be, e.g., low molecular
weight carbohydrates that may be readily soluble in water such as
mannitol, sucrose, lactose, fructose, lactitol or the salts of
monovalent metal ions. The monovalent metal ion include, but are
not limited to, sodium, potassium, lithium, cesium, or rubidium.
The salts of monovalent metal ions as osmotic release modifiers are
selected from the group consisting of, but are not limited to,
sodium citrate, sodium phosphate, sodium bicarbonate, sodium
chloride, potassium nitrate, potassium sulfate and mixtures
thereof. They may be present in amounts of from about 1% by to 20%
by weight, preferably 2% by weight to 10% and most preferably 3% by
weight to 8% by weight of the stable multi-particulate
pharmaceutical composition. The osmotic release modifier is used in
amounts sufficient to cause the pellets to grow in size via the
imbibition of water, and then swell, disintegrate or burst, thereby
allowing for the release of the drug into the gastrointestinal
tract. In preferred embodiments, it was found that the pellets
burst is less than about 3 minutes, preferably, less than about 1
minute. This phenomenon enables the pellets to release the drug
when a large quantity of aqueous medium, such as is present in the
gastrointestinal tract, is available. It will be understood in the
art that for this phenomenon to proceed unhindered, either the
pellets should be uncoated or the coating if any, should be soluble
or easily disintegrated in an aqueous medium. Particularly, the
pellets should be free of a barrier coating such as a coating with
a water insoluble polymer. The release does not occur when the
pellets are sprinkled on soft food and ingested. In embodiments
where pellets are harder because they are made by extrusion and
spheronization, the preferred amount of osmotic release modifier is
in the range of 3% to 8% by weight of the multi-particulate
pharmaceutical composition. In one preferred embodiment of the
present disclosure, the osmotic release modifier is sodium citrate
in an amount from about 1% by to 20% by weight, preferably 2% by
weight to 10% and most preferably 3% by weight to 8% by weight of
the stable multi-particulate pharmaceutical composition.
[0015] The stable multi-particulate pharmaceutical composition
comprises one or more stabilizers which are preferably alkaline
earth metal salts. In one specific embodiment, the stabilizer is a
salt of an alkaline earth metal. In such a specific embodiment, the
stabilizer is not an inorganic substance, such as for example,
titanium oxide or iron oxide, or any other tar-based pigment. When
the stabilizer used is an alkaline earth metal, it is preferably
selected from the group consisting of, but not limited to,
magnesium hydroxide, magnesium oxide, magnesium acetate, calcium
acetate, calcium gluconate, calcium glycerophosphate and aluminum
hydroxide and mixtures thereof. The stabilizer is preferably
present in the multi-particulate pharmaceutical composition in
amounts of from about 1% to about 20% by weight, preferably 2% to
10% by weight and most preferably 3% to 8% by weight of the stable
multi-particulate pharmaceutical composition. In one preferred
embodiment of the present invention, the stabilizer is magnesium
oxide which is present in an amount of from about 1% to 20% by
weight, preferably 2% to 10% by weight and most preferably 3% to 8%
by weight of the stable multi-particulate pharmaceutical
composition.
[0016] Apart from osmotic release modifiers and stabilizers, the
pellets may further comprise conventional excipients, such as
disintegrants, diluents and lubricants. Examples of the
disintegrants that may be used in the pellets include, but are not
limited to, crospovidone, sodium starch glycolate, sodium
croscarmellose, carboxymethylcellulose, low viscosity
hydroxypropylcellulose, potassium polacrilin or mixtures thereof.
The disintegrant may be present in an amount ranging from about 15%
to about 50% by weight, preferably 20% to 35% by weight and most
preferably 25% to 30% by weight of the stable multi-particulate
pharmaceutical composition.
[0017] Examples of the diluents that may be used in the
composition, include, but are not limited to, microcrystalline
cellulose, lactose, starch, magnesium carbonate, maltose, kaolin or
mixtures thereof. The diluents may be present in an amount ranging
from about 15% to about 50% by weight, preferably 20% to 35% by
weight and most preferably 25% to 30% by weight of the stable
multi-particulate pharmaceutical composition.
[0018] In one embodiment, the pellets of the stable
multi-particulate pharmaceutical composition may be prepared by
extrusion and/or spheronization. In one specific embodiment, the
stable multi-particulate pharmaceutical composition may be prepared
by initially mixing rosuvastatin calcium, stabilizer, osmotic
release modifier and other excipients and passing this powder blend
through a suitable sieve. The blend is then granulated with a
suitable granulating agent that may be, for example, purified water
or any binder solution. The wet granules may be extruded and
spheronized. The average particle size of the individual pellets of
the pharmaceutical composition may be determined by sieve analysis
using an ASTM sieve. The sieve analysis is a practice or procedure
used to assess the particle size distribution of a granular
material, wherein the sieve mesh size is represented by a
micrometer average particle size through which the particles pass.
The particle size can also be measured via a laser light
diffraction technique. The laser light diffraction technique used
for the determination of particle size and its distribution is
based on the analysis of the diffraction pattern produced when
particles are exposed to a beam of monochromatic light. In one
embodiment of the present disclosure, the particle size
distribution is determined by following the model of Malvern
Mastersizer: Analysis model: Polydisperse, Presentation: BNJE,
having a range lens: 300 mm, and Beam length of 2.40 mm. The term
D.sub.N value of `x .mu.m` herein means at least about N % of the
total population have a particle size less than `x .mu.m`.
[0019] When the particle size of the pellets is too large, it
provides a gritty feeling when sprinkled on food that is not
acceptable and desirable and may deter the user from administering
the multi-particulate pharmaceutical composition as a sprinkle. The
unique size range of the pellets of the composition of the present
invention does not give a gritty feeling when sprinkled on food and
administered or drank with a liquid vehicle.
[0020] In one specific embodiment, where the pellets are prepared
by extrusion, spheronization, the extrudates so formed may be
sieved to achieve the average diameter of the pellets, preferably
wherein 95% of the pellets pass through size 20 mesh and 100% of
the pellets are retained on size 40 mesh. Typically, in one
specific embodiment, the pellets have an average diameter of from
about 0.1 mm to 0.9 mm, preferably from about 0.2 mm to 0.8 mm and
most preferably the pellets have an average diameter of about
0.4-0.7 microns.
[0021] The rosuvastatin calcium containing pellets may be
optionally, coated with a taste masking coating composition.
Examples of polymers that may be used as a taste masking coating
include, dimethylaminoethyl methacrylate (Eudragit EPO), polyvinyl
alcohol, low viscosity cellulose derivatives and the like and
mixtures thereof. The coated pellets are then lubricated and may be
filled into a capsule or a sachet or a pouch or may be compressed
into a dispersible tablet. In one specific embodiment, the present
invention provides pellets comprising an admixture of rosuvastatin
calcium, magnesium oxide and sodium citrate and other excipients.
The pellets are further coated with a taste masking coating
comprising low molecular weight hydroxypropyl methyl cellulose and
low molecular weight polyethylene glycol. In one specific
embodiment, the present invention provides a stable
multi-particulate pharmaceutical composition comprising pellets,
the pellets comprising a mixture of rosuvastatin or its
pharmaceutically acceptable salts as a sole active ingredient, one
or more osmotic release modifiers and one or more stabilizers,
wherein the particle size of the pellets ranges from about 0.4 mm
to 0.8 mm, the rosuvastatin salt is rosuvastatin calcium, the
stabilizer is an alkaline earth metal salt and the osmotic release
modifier is inorganic salt of monovalent cation.
[0022] In one aspect, the present invention also provides a method
of treating hypercholesterolemia, particularly in subjects having
difficulty swallowing. In one particular aspect, there is provided
a method of treatment of hyperlipidemia, mixed dyslipidemia,
hypertriglyceridemia, homozygous familial hypercholesterolemia, or
primary dysbetalipoproteinemia, slowing the progression of
atherosclerosis, primary prevention of cardiovascular disease, said
method comprising orally administering to a human in need thereof
the stable multi-particulate pharmaceutical composition of the
present invention. The method of treating includes administration
of the pharmaceutical composition of the present invention
comprising administration of from about 5 to about 40 mg of
rosuvastatin composition per day, the quantity being expressed as
the free acid.
[0023] In one embodiment, the stable multi-particulate
pharmaceutical composition filled into a capsule is opened by a
capsule opening device to avoid spillage of the contents of the
capsule while opening the capsule. This is particularly helpful for
geriatric patients who have difficulty opening the capsules to
empty the contents onto soft food. Particularly, the absence of
fines in the multi-particulate pharmaceutical composition avoids
the loss of the composition which may result from blowing of the
fine powder while being emptied from the capsule or pouch onto the
carrier solid or liquid food contents. Alternatively, the pellets
can be administered from a device which dispenses the pellets
directly onto the soft food.
[0024] The following examples illustrate the scope of the present
disclosure without any limitation thereto.
Comparative Example 1
[0025] Rosuvastatin calcium, microcrystalline cellulose, mannitol
and crospovidone were mixed in a polybag and sifted through
suitable sieve. Additional mannitol was dissolved in purified water
and used as a granulating solution. The rosuvastatin calcium
mixture was granulated with the mannitol/purified water solution.
The resulting wet granules were passed through an extruder. The
extrudates were then passed through a spheronizer to form pellets.
The wet pellets were dried and the dried pellets were suitably
sized. A solution of cellulose acetate and polyethylene glycol was
prepared in an acetone and water mixture. The dried pellets were
coated with the above solution. The coated pellets were dried and
lubricated with silicon dioxide. The lubricated pellets were then
filled into hard gelatin capsules.
TABLE-US-00001 TABLE 1 In-vitro dissolution data of Comparative
Example 1 in different dissolution media Time (min) 0.01N HCl, pH
1.2 Acetate buffer, pH 4.5 10 29 41 20 46 60 30 58 71 45 70 82
[0026] From Table 1, it is evident that the Comparative Example 1
provided poor dissolution in 0.01 N HCl as well as acetate buffer.
For instance, in 0.01 N HCl and in an acetate buffer, not more than
about 80% was released, at the end of 30 minutes.
[0027] The filled capsules of Comparative Example 1 were subjected
to accelerated stability studies wherein the filled capsules were
stored at 40.degree. C. and 75% relative humidity for two months
and the results are provided in Table 2.
TABLE-US-00002 TABLE 2 Results of stability study of Comparative
Example 1 Anti- isomer Highest (IMP Lactone Dehydro Dehydro Dehydro
Unknown Total A) 5-keto (IMP B) Acid 3-keto lactone triene impurity
impurities Initial ND 0.35 0.03 0.01 ND ND ND 0.05 0.47 2 months
0.01 0.49 0.46 0.01 ND 0.01 ND 0.06 1.3 40.degree. C./75% RH ND:
not detectable
[0028] From the data given in Table 2, it is evident that the
multi-particulate pharmaceutical composition showed very high total
impurity. For example, the total impurities increased from 0.47% to
1.3% at the end of just two months under accelerated temperature
and humidity conditions. Further the in vitro dissolution was not
satisfactory in that roughly 60%-70% of the rosuvastatin calcium
was released at the end of 30 minutes.
Comparative Example 2
[0029] Trisodium citrate dihydrate was dissolved in water.
Rosuvastatin calcium, microcrystalline cellulose, mannitol and
crospovidone were mixed and sifted through a suitable sieve. This
blend was granulated with the trisodium citrate solution. The wet
granules were extruded through an extruder. The extrudates were
then passed through a spheronizer to form pellets. The pellets were
dried in a fluid bed drier and were suitably sized by passing
through ASTM #20 sieve and collecting the them on ASTM #40 sieve to
have mean size ranging 0.4 mm to 0.8 mm. A solution of low
viscosity hydroxypropyl methyl cellulose and polyethylene glycol
was prepared in isopropyl alcohol and water. The dried pellets were
coated with this solution. The coated pellets were then lubricated
with silicon dioxide and filled into hard gelatin capsule
shells.
TABLE-US-00003 TABLE 3 In-vitro dissolution data of Comparative
Example 2 in various dissolution media Time (min) 0.01N HCl, pH 1.2
Acetate buffer, pH 4.5 10 66 75 20 81 91 30 89 96 45 93 98
[0030] The filled capsules of Comparative Example 2 were subjected
to accelerated and long term stability conditions for three months
at 40.degree. C. and 75% relative humidity and the results are
provided in Table 3 and 4, respectively.
TABLE-US-00004 TABLE 4 Results of the stability study of
Comparative Example 2 Lactone Highest Anti- 5- (IMP Dehydro 3-
Dehydro Dehydro unknown Total isomer keto B) Acid keto lactone
triene impurity impurities Initial 0.01 0.39 0.07 0.01 ND ND ND
0.05 0.60 3 months ND 0.11 1.06 ND ND 0.06 ND 0.33 2.66 40.degree.
C./75% RH ND: not detectable
[0031] From the results of the dissolution tabulated in Table 3
above, it is apparent that capsules of Comparative Example 2
provided satisfactory dissolution. For instance, complete
dissolution of rosuvastatin calcium was observed in 0.01N HCl and
acetate buffer. However, from the results of the stability studies,
given in Table 4, it can be concluded that there is sharp increase
in the rosuvastatin lactone impurity content, highest unknown
impurity and the total impurities, upon exposure to time and
temperature and relative humidity. For instance, at the end of
three months, at 40.degree. C./75% relative humidity, the total
impurities increased from an initial value of 0.60% by weight to
2.66% by weight.
Example 1
[0032] Trisodium citrate dihydrate was dissolved in water.
Rosuvastatin calcium, microcrystalline cellulose, mannitol,
crospovidone and magnesium oxide were mixed well and sifted through
a suitable sieve and granulated with the trisodium citrate
solution. The wet granules were extruded through an extruder and
spheronized in a spheronizer. The resulting pellets were then dried
and passed through ASTM #20 sieve and collected on ASTM #40 sieve
to have mean particle size ranging from 0.4 mm to 0.8 mm.
[0033] A solution of low viscosity hydroxypropyl methyl cellulose
and polyethylene glycol was prepared in an isopropyl alcohol and
water mixture. The rosuvastatin calcium pellets were coated with
the solution and dried. The coated pellets were mixed with silicon
dioxide. The resulting lubricated pellets were filled into hard
gelatin capsule shells.
TABLE-US-00005 TABLE 5 In-vitro dissolution data of Example 1 in
various dissolution media Time (min) 0.01N HCl, pH 1.2 Acetate
buffer, pH 4.5 5 70 67 10 90 91 20 96 98 30 96 99 45 97 100
[0034] The above capsules filled with pellets were subjected to
accelerated, intermediate and long term stability conditions, and
the chemical analysis in terms of assay, and known and unknown
impurities was performed, as shown in Table 6.
TABLE-US-00006 TABLE 6 Results of the stability study of the
pharmaceutical composition of Example 1 Highest Anti- 5- Dehydro 3-
Dehydro Dehydro unknown Total isomer keto Lactone Acid keto lactone
triene impurity impurities Initial ND 0.39 ND 0.01 ND 0.01 ND 0.05
0.61 6 months ND 0.06 0.02 0.01 ND ND ND 0.18 0.67 40.degree.
C./75% RH ND: not detectable
[0035] It can be observed from Table 5 that the multi-particulate
pharmaceutical composition of the present invention showed complete
dissolution in various dissolution media. Further, it is evident
from the above Table 6, that rosuvastatin lactone impurity levels
remained substantially unchanged as compared to the initial
concentration. This is remarkable when compared to the results of
Comparative Examples 1 and 2.
* * * * *